Similar results were seen in standard-risk patients, such as patients with a TEL/AML1 fusion gene, in whom engraftment of B-ALL was restricted to cells containing the CD19+ phenotypes[154]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.